THC — Tenet Healthcare Corporation Stock Price, Chart & AI Report

Neutral Oct 9, 2026 • 21:00 UTC Zacks Investment Research • Zacks.Com

Tenet Healthcare (THC) Beats Stock Market Upswing: What Investors Need to Know

Tenet Healthcare closed at $263.78, up 1.23% and outpacing the S&P 500's 0.6% gain. The hospital operator is expected to report Q3 EPS of $4.59 (up 24.05% YoY) and revenue of $5.47 billion (up 3.4% YoY) on October 29, 2026. With a Zacks Rank of #3 (Hold) and Forward P/E of 12.39, THC trades in line with its industry average valuation.

THC Tenet Healthcare hospital operator earnings report stock performance Medical sector Zacks Rank valuation metrics

Sentiment note

While THC outperformed the broader market on the trading day and shows strong earnings growth expectations (24% EPS growth), the stock has declined 1.1% over the past month and received a Zacks Rank of #3 (Hold). The valuation metrics are in line with industry averages with no significant deviation, suggesting fair but not compelling value. The modest recent estimate revision (-0.02%) indicates stable but not improving analyst sentiment.

Positive Oct 8, 2026 • 12:40 UTC Zacks Investment Research • Na

Why Tenet Healthcare (THC) is a Top Value Stock for the Long-Term

Tenet Healthcare (THC) receives a #3 (Hold) rating on the Zacks Rank with a VGM Score of B. The company benefits from attractive valuation metrics including a forward P/E ratio of 12.35 and a Value Style Score of A. Two analysts revised earnings estimates upward in the last 60 days, with the Zacks Consensus Estimate increasing $0.75 to $21.04 per share, and the company maintains an average earnings surprise of +22.7%.

THC Tenet Healthcare Zacks Rank Value Score earnings estimate revision healthcare services stock rating

Sentiment note

Despite a Hold (#3) rating, THC demonstrates positive fundamentals with an A Value Style Score, attractive forward P/E of 12.35, upward earnings estimate revisions from two analysts, and a strong average earnings surprise of +22.7%. These factors suggest solid value and growth potential for investors.

Neutral Oct 8, 2026 • 12:00 UTC Zacks Investment Research • Zacks.Com

Tenet Healthcare Corporation (THC) is Attracting Investor Attention: Here is What You Should Know

Tenet Healthcare (THC) is receiving increased investor attention. The stock has underperformed the S&P 500 over the past month (-3.4% vs +1.4%). While the company beat earnings and revenue estimates in recent quarters with strong EPS growth of +25.4% expected for the current fiscal year, the Zacks Rank #3 (Hold) rating suggests the stock may perform in line with the broader market in the near term. The company trades at a valuation discount to peers.

THC Tenet Healthcare hospital operator earnings estimates revenue growth valuation Zacks Rank stock performance

Sentiment note

While Tenet shows strong fundamental metrics (25.4% earnings growth, consistent beat on estimates, attractive valuation with grade A), the Zacks Rank #3 (Hold) rating and recent underperformance (-3.4% vs market +1.4%) suggest near-term performance will be in line with the broader market. The mixed signals between strong fundamentals and neutral near-term outlook warrant a neutral stance.

Neutral Oct 2, 2026 • 21:00 UTC Zacks Investment Research • Zacks.Com

Tenet Healthcare (THC) Outpaces Stock Market Gains: What You Should Know

Tenet Healthcare stock rose 1.83% to $258.62, outperforming the S&P 500's 0.73% gain. The hospital operator is projected to report Q3 EPS of $4.59 (up 24.05% YoY) and revenue of $5.47 billion (up 3.4% YoY). For the full year, earnings are forecast at $21.04 per share and revenue at $22.2 billion. THC holds a Zacks Rank #3 (Hold) with a Forward P/E of 12.07 and PEG ratio of 0.97.

THC hospital operator earnings growth stock performance valuation metrics Zacks Rank

Sentiment note

While THC showed strong recent performance (+1.83% daily, outperforming S&P 500) and impressive earnings growth projections (+24.05% EPS YoY), the Zacks Rank #3 (Hold) rating and recent monthly depreciation (-3.61% over past month) suggest a balanced outlook. The valuation metrics (Forward P/E 12.07, PEG 0.97) are in line with industry averages, indicating fair but not exceptional value.

Positive Sep 30, 2026 • 15:57 UTC Zacks Investment Research • Na

Can THC's Cash Flow Support Its Expanding Capital-Return Strategy?

Tenet Healthcare (THC) is accelerating share buybacks and raising 2026 free cash flow guidance to $1.825-$2.055 billion, supported by 27.1% year-over-year growth in operating cash flow to $2.2 billion. The company has $2.1 billion remaining in buyback authorization while continuing to invest in growth initiatives and managing debt obligations.

THC UHS HCA share buybacks cash flow capital allocation healthcare shareholder returns

Sentiment note

Strong operating cash flow growth of 27.1%, raised free cash flow guidance, increased buyback authorization by $2 billion, and $1.4 billion spent on repurchases in H1 2026 demonstrate robust financial health and confidence in future performance.

Positive Sep 30, 2026 • 12:45 UTC Zacks Investment Research • Na

Here's Why Tenet Healthcare (THC) is a Strong Growth Stock

Tenet Healthcare (THC) is featured as a stock to watch with a #3 (Hold) Zacks Rank and an A VGM Score. The company shows strong growth prospects with forecasted year-over-year earnings growth of 25.4% for the current fiscal year, supported by three upward earnings estimate revisions in the last 60 days and an average earnings surprise of +22.7%.

THC Tenet Healthcare stock rating growth investing earnings growth Zacks Rank Style Scores

Sentiment note

THC receives positive sentiment due to its strong growth fundamentals including 25.4% forecasted year-over-year earnings growth, three upward earnings estimate revisions in 60 days, A-rated VGM and Growth Style Scores, and a notable +22.7% average earnings surprise, making it attractive for growth investors despite its Hold ranking.

Positive Sep 22, 2026 • 15:14 UTC Zacks Investment Research • Na

Can Pediatrix Sustain Growth Despite Lower Patient Volumes?

Pediatrix Medical Group (MD) reported 4% YoY revenue growth to $487.8 million in Q2 2026, driven by improved reimbursement and higher patient acuity, offsetting a 2.1% decline in patient volumes. The company reaffirmed its 2026 adjusted EBITDA guidance of $280-$300 million, though volume trends and easing collection benefits remain key risks.

MD THC HCA Pediatrix Medical Group Q2 2026 earnings revenue growth patient volumes reimbursement

Sentiment note

Tenet is benefiting from stronger hospital activity with 6% YoY revenue growth and 2.3% admission increases, supported by higher acuity care and expanding ambulatory services, demonstrating stronger operational momentum than peers.

Neutral Sep 20, 2026 • 00:05 UTC The Motley Fool • Jack Delaney

Tenet Healthcare Director Nadja West Sells 1,152 Shares

Tenet Healthcare Director Nadja West sold 1,152 shares (5% of her direct holdings) on September 2, 2026, for approximately $298,138 at $258.80 per share. West retained 23,653 shares valued at $6.1 million, indicating continued confidence in the company. Analysts view the sale as routine profit-taking following strong 39% one-year stock performance.

THC insider trading stock sale Tenet Healthcare director sale healthcare sector profit-taking

Sentiment note

The insider sale is characterized as routine profit-taking rather than a sign of concern. The director retained substantial holdings (23,653 shares worth $6.1M), demonstrating continued alignment with the company. The stock has significantly outperformed the market (39% vs S&P 500's 14.8% over one year), and 83% of analysts rate it a buy with a median price target of $284, suggesting positive long-term outlook despite the modest near-term gain potential of 8.4%.

Neutral Sep 15, 2026 • 13:30 UTC Zacks Investment Research • Na

Wall Street Analysts Think Tenet (THC) Is a Good Investment: Is It?

The article examines the reliability of Wall Street analyst recommendations versus Zacks Rank for stock picking. Using Tenet Healthcare as an example, it explains why brokerage recommendations often show positive bias due to vested interests, and argues that Zacks Rank—based on earnings estimate revisions—is a more reliable predictor of near-term stock price movements. Tenet received a Buy-equivalent average brokerage recommendation but a Zacks Rank #2 (Buy), with recent earnings estimates showing modest growth.

THC brokerage recommendations analyst bias Zacks Rank earnings estimate revisions stock rating systems investment strategy price prediction

Sentiment note

While Tenet received a Buy-equivalent average brokerage recommendation (ABR 1.30) with 77.3% Strong Buy ratings, the article cautions against relying solely on this due to analyst bias. The Zacks Rank #2 (Buy) is more moderately positive, based on modest earnings estimate revisions (+0.3% over the past month). The sentiment is neutral because the article presents this as a case study to illustrate methodological differences rather than making a strong investment case.

Positive Sep 14, 2026 • 16:27 UTC Zacks Investment Research • Na

Here's Why Tenet Healthcare Shares are Attracting Investors Now

Tenet Healthcare (THC) is experiencing strong growth driven by higher-acuity services, robust commercial revenues, and expansion of its USPI ambulatory care platform. The company raised its 2026 EBITDA outlook and continues to balance growth investments with share buybacks. However, rising operating expenses from elevated labor costs and medical supplies pose a margin pressure risk.

THC UNH GMED CNC healthcare services ambulatory surgery centers higher-acuity demand commercial revenues

Sentiment note

THC demonstrates strong fundamentals with 25.4% expected earnings growth, 9.3% USPI revenue growth, raised 2026 EBITDA guidance, consistent earnings beat history (22.7% average surprise), and superior return on assets (5.6% vs 4.4% industry average). The company is successfully expanding its ambulatory platform and managing capital allocation through buybacks.

Neutral Sep 14, 2026 • 10:20 UTC Zacks Investment Research • Zacks.Com

Should You Invest in the State Street SPDR S&P Health Care Services ETF (XHS)?

The State Street SPDR S&P Health Care Services ETF (XHS) is a passively managed healthcare services sector ETF with low costs (0.35% expense ratio) and solid year-to-date performance of 27.29%. The fund holds about 62 healthcare companies with a medium risk profile (beta of 0.93) and carries a Zacks ETF Rank of 3 (Hold), making it a reasonable option for investors seeking diversified healthcare sector exposure.

XHS THC WGS NEO healthcare services ETF passive management sector exposure low expense ratio

Sentiment note

Listed as the largest holding in XHS at 2.56% of assets, but no specific performance commentary or analysis is provided in the article.

Positive Sep 2, 2026 • 12:04 UTC Zacks Investment Research • Zacks Equity Research

Tenet Healthcare and Archrock have been highlighted as Zacks Bull and Bear of the Day

Tenet Healthcare (THC) is highlighted as the Bull of the Day with a Zacks Rank #1 (Strong Buy) due to strong Q2 earnings that beat expectations by 50%, 26 consecutive quarters of earnings beats, and attractive valuation at 12.6X forward earnings. Archrock (AROC) is the Bear of the Day with a Zacks Rank #5 (Strong Sell) following back-to-back earnings misses, reduced guidance, and declining EPS estimates. The article also provides analysis on NextEra Energy (NEE), FirstEnergy (FE), and PPL Corp. (PPL) regarding AI-driven data center demand opportunities.

THC AROC NEE NEEPN healthcare stocks earnings surprise valuation natural gas compression

Sentiment note

Strong Q2 results with 50% EPS surprise, 26 consecutive quarters of earnings beats, raised full-year guidance, surging analyst EPS revisions (+17% over 60 days), attractive valuation at 12.6X forward earnings (below sector average), and strong price performance (36% YTD, 250% over 5 years). Zacks Rank #1 (Strong Buy).